Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Published:2020-09 Issue:9 Volume:18 Page:1248-1269
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Gerds Aaron T.¹,Gotlib Jason²,Bose Prithviraj³,Deininger Michael W.⁴,Dunbar Andrew⁵,Elshoury Amro⁶,George Tracy I.⁴,Gojo Ivana⁷,Gundabolu Krishna⁸,Hexner Elizabeth⁹,Hobbs Gabriela¹⁰,Jain Tania⁷,Jamieson Catriona¹¹,Kuykendall Andrew T.¹²,McMahon Brandon¹³,Mohan Sanjay R.¹⁴,Oehler Vivian¹⁵,Oh Stephen¹⁶,Pardanani Animesh¹⁷,Podoltsev Nikolai¹⁸,Ranheim Erik¹⁹,Rein Lindsay²⁰,Salit Rachel¹⁵,Snyder David S.²¹,Stein Brady L.²²,Talpaz Moshe²³,Thota Swapna⁶,Vachhani Pankit²⁴,Wadleigh Martha²⁵,Walsh Katherine²⁶,Ward Dawn C.²⁷,Bergman Mary Anne²⁸,Sundar Hema²⁸

Affiliation:

1. 1Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

2. 2Stanford Cancer Institute;

3. 3The University of Texas MD Anderson Cancer Center;

4. 4Huntsman Cancer Institute at the University of Utah;

5. 5Memorial Sloan Kettering Cancer Center;

6. 6Roswell Park Comprehensive Cancer Center;

7. 7The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

8. 8Fred & Pamela Buffett Cancer Center;

9. 9Abramson Cancer Center at the University of Pennsylvania;

10. 10Massachusetts General Hospital Cancer Center;

11. 11UC San Diego Moores Cancer Center;

12. 12Moffitt Cancer Center;

13. 13University of Colorado Cancer Center;

14. 14Vanderbilt-Ingram Cancer Center;

15. 15Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

16. 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

17. 17Mayo Clinic Cancer Center;

18. 18Yale Cancer Center/Smilow Cancer Hospital;

19. 19University of Wisconsin Carbone Cancer Center;

20. 20Duke Cancer Institute;

21. 21City of Hope National Medical Center;

22. 22Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

23. 23University of Michigan Rogel Cancer Center;

24. 24O'Neal Comprehensive Cancer Center at UAB;

25. 25Dana-Farber/Brigham and Women’s Cancer Center;

26. 26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

27. 27UCLA Jonsson Comprehensive Cancer Center; and

28. 28National Comprehensive Cancer Network

Abstract

Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/18/9/article-p1248.xml

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature;Virchows Archiv;2023-11-20

2. The multidisciplinary approach to eosinophilia;Frontiers in Oncology;2023-05-18

3. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes;Orphanet Journal of Rare Diseases;2023-04-30

4. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group;Leukemia;2023-04-19

5. What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias;Hemato;2023-03-29